FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
3,819 letters. Newest first.
-
FoodVivot LLC
FDA warns Vivot LLC it lacked required foreign supplier food-safety checks for imported matcha and green tea.
Medium -
FoodImu-Tek Animal Health, Incorporated
FDA warns Imu-Tek Animal Health over unapproved drug claims and manufacturing failures for Colostrom-5 products.
High risk -
DrugsJubilant HollisterStier General Partnership
FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
High risk -
FoodPamex Foods Incorporated
Pamex Foods, a Maryland importer, had no FSVP records for three imported foods and never registered its facility.
High risk -
FoodGlobal Imports Origins
FDA warns Global Imports Origins of Houston, TX, for lacking a foreign supplier verification program for imported Red Pepper.
Medium -
FoodGreat Enterprise - Group - Inc.
FDA says Great Enterprise Group, a Honolulu food importer, had no Foreign Supplier Verification Program for sauces, bamboo shoots and rice sticks.
High risk -
DrugsNativeMed LLC dba NativeMed
FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsHydraMed IV LLC dba HydraMed
FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsNexus Health Solutions LLC dba Harper Meds
FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Low -
DrugsFitRX, LLC dba AM RX
FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsAltru Telehealth, LLC dba Altru Telehealth
FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
Low -
DrugsEden Health International Inc. dba Eden
FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsTrinity HealthCare Supply, LLC dba altRx
FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.
Low -
FoodYS Group Inc.
YS Group Inc. of Arcadia, CA, imported tofu skin, dried seaweed and buckwheat flour without any FSVP, FDA says.
Medium -
DrugsAmie Health, Inc. dba Amie
FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsThrivelab Co. dba Thrivelab
FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.
Medium -
DrugsVivioMD Group LLC dba VivioMD
FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.
Low -
DrugsGlow Medispa, LLC dba Mint Med
FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
Low -
DrugsNexlife Inc. dba Nexlife
FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsEzra Holdco LLC dba Ezra
FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.
Low -
DrugsReady Med
FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.
Low -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsOrderlyMeds LLC dba OrderlyMeds
FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.
Low -
DrugsRoen Health, Inc. dba RoenRx
FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.
Medium -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsNova Vascular LLC dba NOVARX
FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.
Low -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsMaximus Health, Inc. dba Maximus
FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.
Low -
DrugsSante Manufacturing Inc.
Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
High risk -
DrugsInvaDerm, Inc.
FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.
High risk -
FoodSL Follen Company
FDA says SL Follen Company lacked required foreign supplier verification for imported fresh pineapple.
Medium -
FoodM G R Produce LLC
FDA warns Houston produce importer M G R Produce for lacking an FSVP for imported scallions, jicama, and jalapenos.
Medium -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DevicesZOLL Medical Corporation
FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.
High risk -
DevicesHappiest Baby, Inc.
FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.
High risk -
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsGopaldas Visram & Co., Ltd.
FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsRevlon Group Holdings, LLC
FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.
High risk -
DrugsUmendra Life Sciences Private Limited
Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.
High risk -
DrugsErkul Kozmetik Sanayi ve Ticaret A.S.
Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.
High risk -
DrugsPLZ Corp
FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
High risk -
DrugsAsanuma Corporation - Sagamihara Factory
FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
High risk -
DrugsShantou Qiwei Industry Co., LTD
FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.
High risk -
DrugsZydus Lifesciences Limited
FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.
High risk -
DrugsMacau-Union Pharmaceutical Limited
Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.
High risk